The global asthma therapeutics market size was valued at USD 27.81 billion in 2024 and is anticipated to reach around USD 46.66 billion by 2034, growing at a CAGR of 5.31% from 2025 to 2034.
The U.S. asthma therapeutics market size was estimated at USD 10.64 billion in 2024 and is projected to hit around USD 17.85 billion by 2034, growing at a CAGR of 4.81% during the forecast period from 2025 to 2034.
North America dominated the market and accounted for a share of 51.00% in 2024. This is due to the strong presence of major key players, well-established infrastructure, and increasing prevalence of diseases in the region. For instance, asthma affects more adult women than adult men in the U.S. According to the CDC’s 2020 report, approximately 25 million people in the U.S. were reported to have asthma. In addition, according to the Asthma and Allergy Foundation of America (AAFA), around 5 million children in the U.S. are asthmatic. Furthermore, rising air pollution, increasing geriatric population, and growing demand for fast-acting & high efficacy drugs are a few other factors propelling market growth in North America.
Asia Pacific is anticipated to witness significant growth due to improving healthcare reforms.Other factors contributing to market growth include rising geriatric population, entry of new players, growing healthcare expenditure, and high awareness about lung diseases. In Southeast Asia, asthma is reported as one of the most common non-communicable diseases and is responsible for nearly 73% of the visits to outpatient clinics. This creates a wide target population pool for effective therapeutics.
The global increase in the prevalence of asthma has significantly raised the demand for therapeutics, including the most promising asthma treatment choices. In addition, new therapies, including anti-immunoglobulin E (IgE) antibodies, cytokine modulators, and DNA vaccinations, are now utilized for uncontrolled asthma. The anti-IgE monoclonal antibody (ibalizumab) effectively treats severe allergic asthma. The introduction or approval of these newly developed biologics is anticipated to reshape the treatment landscape, boosting the market growth from 2024 to 2034.
Despite the availability of suitable treatment offerings, the rising incidence of uncontrolled asthma has driven the demand for several & effective treatments. Existing medications fall short of addressing the frequency of asthma attacks. Consequently, key companies are developing novel, effective biological-based therapies with target-specific mechanisms.In February 2023, Pulmatrix initiated a Phase 2b trial, dosing the first patient with PUR1900 for Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma. The global study will assess safety, tolerability, and efficacy over 16 weeks, supporting Pulmatrix's collaboration with Cipla to bring therapy to patients with asthma, with proof-of-concept data expected by mid-2024.
Positive trial results enhance Pulmatrix's market standing and contribute to market growth. Furthermore, the Asthma and Allergy Foundation of America (AAFA) offers an online community for patients, fostering connections and providing EXHALE strategies. Initiatives include promoting NAEPP EPR-4 guidelines, enhancing patient knowledge, forming partnerships with health departments, and launching national programs on respiratory illnesses & inhaler usage. These programs contribute to ongoing efforts to raise awareness, educate the public, and support individuals affected by asthma. Thus, the rising number of awareness programs is a key factor positively impacting market growth.
| Report Attribute | Details |
| Market Size in 2025 | USD 29.29 Billion |
| Market Size by 2034 | USD 46.66 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 5.39% |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Drug Class, Product, Route of Administration, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Teva Pharmaceutical Industries Ltd.; GSK plc; Merck & Co., Inc.; F. Hoffmann-La Roche Ltd.; AstraZeneca; Boehringer Ingelheim International GmbH; Sanofi; Koninklijke Philips N.V., BD; Covis Pharma |
The anti-inflammatory segment led the market and accounted for a revenue share of 62.77% in 2024 owing to the introduction of affordable and innovative anti-inflammatory biologics to treat severe asthmatic patients.For instance, in April 2021, the FDA approved Xolair, a biologic, to treat moderate to severe persistent allergic asthma, Chronic Idiopathic Urticaria (CIU), and nasal polyps. It is specifically designed to target and block IgE. Furthermore, collaborations between pharmaceutical companies, research institutions, and healthcare organizations are driving R&D efforts in the market. These partnerships facilitate the discovery and commercialization of novel anti-inflammatory drugs, further propelling segment growth. For instance, in March 2023, Propeller Health and UC Davis Health announced a partnership to provide personalized medicine for patients at high risk of Chronic Obstructive Pulmonary Disease (COPD) and asthma.
The combination therapy segment is expected to register the fastest CAGR from 2025 to 2034. Combination therapy involves using two medications that target inflammation and bronchoconstriction, two key components of asthma pathophysiology. Adoption of combination therapy is driven by its efficacy compared to other drug combinations, ease of use, and improved patient compliance. In addition, the availability of several fixed-dose combination inhalers has made combination therapy more convenient for patients, further contributing to its higher adoption. For instance, in June 2022, Glenmark Pharmaceuticals Limited introduced a new fixed-dose combination drug, Indamet, in India for uncontrolled asthma. As a result of these factors, combination therapy is expected to dominate the market in the coming years.
The inhalers segment accounted for the largest revenue share in 2024. This can be attributed to several factors, such as their reliability, versatility, portability, and cost-effectiveness. Moreover, increasing prevalence of asthma & COPD and growing need for emergency treatment alternatives against sudden attacks have contributed to a significant market share of inhalers. The inhalers segment is expected to grow further due to the development of advanced products. For instance, in September 2020, GSK Plc. and Innoviva's triple therapy inhaler, Trelegy Ellipta, was approved in the U.S. for treating asthma and COPD. The nebulizers segment is expected to register the fastest CAGR from 2025 to 2034.
One of the primary drivers is ease of use, making nebulizers particularly suitable for children, elderly patients, and severe asthmatic patients who struggle with inhaler techniques. Moreover, an increase in the adoption of nebulizers in home healthcare and emergency medicine due to associated benefits, such as greater comfort, administration of large dosages facilitating sustained results, and favorable reimbursement scenarios, is expected to drive market growth. Furthermore, continuous advancements in nebulizer technology, such as portable and handheld devices, increase patient compliance and convenience. For instance, in July 2020, OMRON Corporation launched OMRON NE C106, a compressor nebulizer designed to deliver medication directly to the lungs in the form of a mist.
The inhaled route of administration segment accounted for the largest revenue share 40.0 in 2024. The inhaled route of administration is considered to be most effective way of treatment as it allows for targeted delivery of medication to the site of inflammation in the airways. The inhaled route of administration is preferred over oral or injectable routes as it minimizes adverse effects and maximizes therapeutic outcomes. In addition, new product launches and approvals are expected to play a significant role in driving the segment growth. For instance, in July 2023, Viatris, Inc. launched Breyna Inhalation Aerosol, an FDA-approved generic version of Symbicort for asthmatic and COPD patients in the United States.
The oral segment is projected to witness the highest growth rate from 2025 to 2034. The oral route of administration is the most common and convenient method of drug delivery for therapeutics. Oral medications are taken by mouth and absorbed into the bloodstream through the digestive system. This route of administration is well-tolerated and easy to use, making it a popular choice for patients and healthcare providers. Oral medications are easy to take and can be administered at home without requiring specialized equipment or training. The convenience, efficacy, and versatility of oral medications make them a valuable tool for managing asthma, which is expected to boost segment growth.
Some of the key players operating in market include Teva Pharmaceutical Industries Ltd, GSK plc, Merck & Co., Inc. and Koninklijke Philips N.V.
CHIESI USA, Inc. and Areteia Therapeutics are some of the emerging market participants in the asthma therapeutics market.
Asthma Therapeutics Market Top Key Companies:
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Asthma Therapeutics market.
By Drug Class
By Product
By Route of Administration
By Region
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers